Complix focuses on developing Cell-Penetrating Alphabodies (CPABs) that can effectively enter tumor cells and modulate intracellular protein-to-protein interactions. These Alphabodies have a unique stability and versatility that allow for alternative non-injectable routes of administration. Complix has established a strong intellectual property position to protect its Alphabody platform and product portfolio. Their Alphabody-based therapeutics offer advantages over existing protein-based therapies and have the potential to address disease targets that are difficult to reach with antibodies or small molecules.